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Background: Polyamidoamine (PAMAM) and polypropylenimine (PPI) dendrimers are 
the commercially available and most widely used dendrimers in pharmaceutical sciences 
and biomedical engineering. In the present study, the loading and release behaviors of 
generation 3 PAMAM and generation 4 PPI dendrimers with the same amount of surface amine 
groups (32 per dendrimer) were compared using phenylbutazone as a model drug.
Methods: The dendrimer-phenylbutazone complexes were characterized by 1H nuclear magnetic 
resonance and nuclear Overhauser effect techniques, and the cytotoxicity of each dendrimer 
was evaluated.
Results: Aqueous solubility results suggest that the generation 3 PAMAM dendrimer has a 
much higher loading ability towards phenylbutazone in comparison with the generation 4 PPI 
dendrimer at high phenylbutazone-dendrimer feeding ratios. Drug release was much slower from 
the generation 3 PAMAM matrix than from the generation 4 PPI dendrimer. In addition, the 
generation 3 PAMAM dendrimer is at least 50-fold less toxic than generation 4 PPI dendrimer 
on MCF-7 and A549 cell lines.
Conclusion: Although the nuclear Overhauser effect nuclear magnetic resonance results 
reveal that the generation 4 PPI dendrimer with a more hydrophobic interior encapsulates more 
phenylbutazone, the PPI dendrimer-phenylbutazone inclusion is not stable in aqueous solution, 
which poses a great challenge during drug development.
Keywords: dendrimer, polyamidoamine, polypropylenimine, drug delivery, cytotoxicity
Introduction
Dendrimers are synthetic macromolecules with hyperbranched structures, well 
defined ellipsoidal or globular shapes, and precise molecular weights.1,2 In comparison 
with traditional linear polymers, dendrimers have shown the following advantages 
when they are used as drug carriers: high drug loading ability endowed by the large 
  numbers of surface functionalities and interior cavities;3,4 high bioavailability of drugs 
covalently or noncovalently attached to dendrimers because of the high penetration 
ability of   dendrimers across cell membranes and biological barriers;5 reproducible 
  pharmacodynamic and pharmacokinetic behavior of dendrimer-based drug   formulations 
due to their well defined structure and extremely low polydispersity;6 multifunctional 
scaffolds for both targeted diagnosis and therapy given that the dendrimer can be easily 
functionalized with various bioactive moieties;7–9 and stable monomolecular micelles 
in physiological conditions which avoid the disassembly of amphiphilic   polymeric   
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micelles below their critical micelle concentrations.1 
  Integrating these versatile features into a single molecule, 
dendrimers have become competitive   candidates as drug 
carriers in the pharmaceutical industry.10
Up to now, the polyamidoamine (PAMAM) dendrimer 
reported by Tomalia in 1985 and polypropylenimine (PPI) 
dendrimer synthesized by Meijer et al in 1993 are the 
most investigated dendrimers in the fields of drug delivery 
(Scheme 1).11,12 These two commercially available dendrimers   
were synthesized by a divergent strategy, in which the 
  construction of dendrimer takes place in a stepwise manner 
by coupling repeated units to a central core, providing a 
series of radically concentric layers called “generations”.1 
  Structurally, PAMAM dendrimer was synthesized by 
Michael addition of amine with acrylic acid methyl ester, 
followed by the aminolysis of the resulting ester by   ethylene 
diamine to create new reaction sites for further Michael 
additions.11 Similarly, PPI dendrimer was initiated by the 
Michael addition of amine with acrylonitrile and followed by 
the reduction of nitrile groups to yield primary amine groups 
which provides new branching points.12
PAMAM and PPI dendrimers have excellent aqueous sol-
ubility which ensures stable aqueous dispersion of PAMAM-
based and PPI-based drug formulations.1 Full-generation 
PAMAM and PPI dendrimers are usually terminated with 
primary amine groups (pKa about 10.0), and the cationic 
surface of PAMAM and PPI can bind a large amount of 
negatively charged drugs through electrostatic   interactions.13 
Low-generation PAMAM and PPI dendrimers have an open 
structure with an ellipsoidal shape and inner pockets which 
can be used to encapsulate hydrophobic drugs.14,15 The pre-
dominant difference in the structure of PAMAM and PPI 
is their interior pockets, ie, PAMAM has relatively polar 
pockets consisting of alkyl chain, tertiary amine, and amido 
groups, while PPI possesses nonpolar pockets consisting 
of alkyl chain and tertiary amine groups.16 In addition, the 
length of branching units for PAMAM (seven bonds) is 
different from that of PPI dendrimer (four bonds), indicat-
ing that the size of PAMAM dendrimer is much larger than 
that of PPI dendrimer with an equivalent number of surface 
amine groups. These structural differences may have inter-
esting physicochemical implications for the host behavior 
of PAMAM and PPI dendrimers. The binding constants of 
dendrimer and phenol blue are an order of magnitude larger 
for PPI versus PAMAM with the same amount of surface 
groups, indicating fewer polar pockets of PPI dendrimer.16 
Dendrimer with a PPI core and a PAMAM shell encapsulates 
hydrophobic pyrene molecules in the PPI layers rather than 
in the PAMAM layers.17 Also, PAMAM and PPI dendrimers 
exhibited distinct behaviors in their ionic interactions with 
negatively charged guests, such as vitamins C, B3, and B6.18 
In a separate study, isobutyramide-terminated PPI dendrimer 
was found to be more hydrophobic than PAMAM dendrimer 
with an equivalent number of isobutyramide groups,19 prob-
ably due to the higher density of surface groups and the more 
hydrophobic interior of PPI dendrimer.
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Scheme 1 Molecular structures of PAMAM (A) and PPI (B) dendrimers.
Abbreviations: PAMAM, polyamidoamine; PPI, polypropylenimine.
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In our previous studies, we have demonstrated that 
PAMAM dendrimers are able to solubilize different families 
of hydrophobic drugs.20 In comparison with interior encapsu-
lation, surface ionic interaction was found to be the major fac-
tor on the solubilization behavior of PAMAM dendrimer.3,13 
The host behaviors of PAMAM dendrimer towards a list 
of drugs were analyzed by 1H nuclear magnetic resonance 
(NMR) titrations,21 nuclear Overhauser effect spectroscopy 
(NOESY),3 and pulsed-field gradient NMR.22 The release of 
drugs from the PAMAM dendritic matrix depends on den-
drimer generation and surface functionality, ionic strength, 
pH conditions, and the solvent.21 PAMAM dendrimer exhib-
its low biocompatibility in A549 and MCF-7 cell lines, and 
the removal of surface charges on PAMAM dendrimer by 
acetylation can completely neutralize the cytotoxic activity of 
dendrimer on these cells.23 All these studies suggest that the 
surface amine groups on PAMAM dendrimers are of central 
importance in the binding, release, and biocompatibility of 
this polymeric nanocarrier. Furthermore, PPI dendrimers 
were also able to enhance the solubility of hydrophobic drugs, 
increase their stability, and prolong their delivery in different 
routes.24 However, systematic comparisons on the loading 
and release behaviors of PAMAM and PPI dendrimer as well 
as their complex structures with drugs are limited.
In this present study, we focused on comparing PPI 
and PAMAM dendrimers in five aspects, ie, drug   loading 
  efficiency, host-guest chemistry, complex stability, in vitro 
drug release behavior, and cytotoxicity. It should be noted that 
PPI and PAMAM dendrimers having the same number of sur-
face amine groups do not share the same   dendrimer   generation. 
For example, both generation 4 PPI and   generation 3 PAMAM 
dendrimers have 32 amine groups on their peripheries. Here, 
they were chosen as model   dendrimers to compare the host 
behaviors of PPI and PAMAM  dendrimers. Phenylbutazone 
was used as a model drug.
Materials and methods
Materials
Generation 4 diaminobutane-cored and amine-terminated 
PPI dendrimer was purchased from Sigma-Aldrich   
(St Louis, MO). Generation 3–5 ethylenediamine-cored 
and amine-  terminated PAMAM dendrimer was purchased 
from   Dendritech Inc (Midland, MI). Phenylbutazone was 
purchased from Shangqiu Tiankang Fine Chemical Co, Ltd 
(Henan, China). Methanol of high-performance liquid 
chromatography (HPLC) grade was purchased from Fisher 
Scientific (Fair Lawn, NJ). Acridine orange and ethidium 
bromide were gifts from the School of Life Sciences, 
East China Normal   University. Deuterium oxide (D2O) 
was obtained from   Beijing Chongxi High-Tech Incubator 
Co, Ltd (Beijing, China). Generation 3 PAMAM dendrimer 
was stored in methanol and the solvent was distilled before 
use. PAMAM and PPI dendrimers were prepared in aqueous 
solutions at a concentration of 10 mg/mL, which were used 
as stock solutions. The dendrimers and the other chemicals 
were used as received without further purification.
Phase solubility test
The solubilities of hydrophobic drugs such as phenylbutazone 
in PAMAM and PPI dendrimer solutions were conducted 
using the Higuchi–Connors method as described elsewhere.25 
A 2 mg sample of phenylbutazone was added into 1.5 mL 
Eppendorf microtest tubes before the drug solubility test, fol-
lowed by addition of PAMAM and PPI dendrimer solutions 
at different concentrations (dendrimer concentration ranges 
from 0.07 to 0.36 mM). The dendrimer-drug suspensions 
were shaken (300 rpm) at room temperature for 24 hours to 
obtain a saturated phenylbutazone solution, and the mixtures 
were then centrifuged twice at 10,000 rpm for 5 minutes to 
remove undissolved drugs. The drug concentrations in the 
supernatants were analyzed using an HPLC method.
gradient-feed method
A 10 mg/mL phenylbutazone solution was prepared by dis-
solving the drug in methanol. Drug solutions (40 µL) were 
added into Eppendorf microtest tubes, and the solvents in 
the tubes were removed to obtain phenylbutazone powder 
(0.4 mg in each tube). Herein, we used a gradient-feed 
method to compare the drug-loading abilities of PAMAM and 
PPI dendrimers. Generally, 4 mL of PAMAM or PPI solution 
(0.14 mM) was added into a microtest tube containing 0.4 mg 
phenylbutazone. The tube was then sonicated for 2 hours to 
ensure the drugs were dissolved in the dendrimer solution, 
followed by transfer of the mixture into a second tube with 
the same amount of phenylbutazone, and sonication of the 
dendrimer-drug mixture. The procedures were repeated until 
the solution was transferred into the twentieth tube. In each 
time interval, 10 µL of the supernatant from the dendrimer-
drug mixture was withdrawn from the tubes and analyzed 
by an HPLC method to determine the drug concentrations 
in the dendrimer solutions. Three repeats were conducted 
for each sample.
HPLC method
The samples were analyzed using a reverse-phase HPLC 
instrument (Agilent 1200, Agilent, Chicago, IL) with a 
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C18 column (4.6 mm diameter, 150 mm length, 5 µm particle 
size, Zorbax Eclipse XDB, Agilent) at 25°C. The mobile 
phase was methanol and water at a ratio of 55:45 with a flow 
rate of 1.0 mL/minute. A volume of 10 µL sample solution 
was injected and the phenylbutazone was detected at a wave-
length of 264 nm. The retention time of phenylbutazone is 
3.8 ± 0.3 minute. Phenylbutazone solutions (methanol) at 
  different concentrations were prepared to obtain a standard 
curve for the drug. The drug concentration correlated linearly 
with the peak area in HPLC ranges from 0.0005 to 0.01 mg/mL   
(R = 0.9991).
1H NMR and NOESY analysis
1H NMR and two-dimensional NOESY experiments were 
obtained on a Bruker Advance 500.132 mHz NMR spec-
trometer at 298.2 ± 0.2 K for dendrimers and dendrimer-drug 
complexes (0.57 mM generation 3 PAMAM or generation 4 
PPI and 18 mM phenylbutazone in D2O).
Chemical shift assignments of the proton peaks in den-
drimers and dendrimer-drug complexes are listed as follows. 
1H NMR for PPI dendrimer: 1.60 ppm (120H, br, −NCH2 
CH2CH2N−, HA); 2.44 ppm (116H, br, −NCH2CH2CH2N−, 
HB); 2.48 ppm (64H, br, −NCH2CH2CH2NH2, HB′); 2.60 ppm 
(64H, br, −NCH2CH2CH2NH2, HC).
1H NMR for PAMAM dendrimer: 2.39 ppm (120H, 
br, −NCH2CH2CONH−, Ha); 2.60 ppm (56H, br, −CONH 
CH2CH2N−, Hb); 2.69 ppm (120H, br, −NCH2CH2CONH−, 
Hc); 2.79 ppm (64H, br, −CONHCH2CH2NH2, Hb′);   
3.21 ppm (56H, br, −CONHCH2CH2N−, Hd); 3.26 ppm (64H, 
br, −CONHCH2CH2NH2, Hd′).
1H NMR for PPI−phenylbutazone complex: 0.86 ppm 
(3H, br, −CH2CH3, H8); 1.29 ppm (2H, br, −CH2CH2CH3, H7); 
1.41 ppm (2H, br, −CH2CH2CH2−, H6); 1.57 ppm (120H, br,   
−NCH2CH2CH2N−, HA); 2.14 ppm (2H, br, −CH−CH2−CH2−, 
H5); 2.30 ppm (116H, br, −NCH2CH2CH2N−, HB);   
2.38 ppm (64H, br, −NCH2CH2CH2NH2, HB′); 2.63 ppm   
(64H, br, −NCH2CH2CH2NH2, HC); 7.07 ppm (2H, br, Ar, H1);   
7.24 ppm (4H, br, Ar, H3); 7.29 ppm (4H, br, Ar, H2).
1H NMR for PAMAM−phenylbutazone complex: 0.85 ppm   
(3H, br, −CH2CH3, H8); 1.28 ppm (2H, br, −CH2CH2CH3, 
H7); 1.40 ppm (2H, br, −CH2CH2CH2−, H6); 2.14 ppm (2H, 
br, −CH−CH2−CH2−, H5); 2.30–2.35 ppm (120H, br, −NCH2 
CH2CONH− Ha); 2.50 ppm (56H, br, −CONHCH2CH2N−, 
Hb); 2.72 ppm (120H, br, −NCH2CH2CONH−, Hc); 2.89 ppm   
(64H, br, −CONHCH2CH2NH2, Hb′); 3.19 ppm (56H, br, 
−CONHCH2CH2N−, Hd); 3.31 ppm (64H, br, −CONH 
CH2CH2NH2, H d′); 7.08 ppm (2H, br, Ar, H1); 7.25 ppm   
(8H, br, Ar, H2,3).
For the two-dimensional NOESY experiment, 300 msec 
was chosen as the mixing time for the optimization of 
cross-peak intensities with minimum distortions during the 
period for NOE establishment. A certain amount of ethanol 
was added to the dendrimer-drug solutions as an internal 
standard. A relaxation delay of one second, an acquisition 
time of 213 msec, and a 90° pulse width of 7.7 µ were used. 
Sixteen transients were collected over 800 complex points 
in the t1 dimension. The data were processed by NMR Pipe 
software on a Linux system with standard Lorents-Gauss 
window function and zero filling in both dimensions. All 
data were shown with Sparky software.
In vitro drug release studies
The in vitro release behavior of phenylbutazone from 
PAMAM or PPI dendrimer matrixes in aqueous solutions 
was investigated. Dendrimer-phenylbutazone complexes 
were prepared by dissolving 1 mg drug in 2 mL 0.14 mM 
  generation 3 PAMAM or generation 4 PPI dendrimer 
  solutions. The dendrimer-drug mixture was sonicated for 
2 hours and transferred into a dialysis bag with a molecular 
weight cutoff of 1000 Da, which was immediately immersed 
into 50 mL distilled water. The molecular weights for 
  generation 3 PAMAM and generation 4 PPI dendrimers are 
6900 Da and 3513 Da, respectively. The dendrimers and 
  dendrimer-drug complexes were kept inside the dialysis bag 
while the free phenylbutazone molecules with a molecu-
lar weight of 308 Da released into the outer phase of the 
dialysis bag. At specific time intervals, 30 µL samples were 
withdrawn from the outer phase which was replenished with 
30 µL distilled water. The phenylbutazone concentrations in 
the samples were analyzed using the HPLC method. Three 
repeats were conducted for each sample.
Cell culture and cytotoxicity assay
MCF-7 and A549 cells (American Type Culture Collection, 
Manassus, VA) were incubated at 37°C in 5% CO2 and 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco Inc, 
Carlsbad, CA) supplemented with streptomycin 100 µg/mL,   
penicillin sulfate 100 U/mL, and 10% heat-inactivated fetal 
calf serum (Gibco Inc). The cytotoxicity of generation 3 
PAMAM and generation 4 PPI dendrimers on both cells 
were evaluated using a 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay, which is the 
most frequently used method for measuring cell proliferation 
and viability. MCF-7 or A549 cells were seeded in 96-well 
culture plates for 48 hours at a density of 104 cells per well 
before the cytotoxicity assay. After that, the cells were treated 
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with DMEM containing different concentrations of PAMAM 
or PPI dendrimers (dendrimer concentration ranges from 
3.62 × 10−7 M to 7.25 × 10−5 M) for 48 hours, followed by 
removal of the medium, washing of the MCF-7 or A549 cells 
twice with fresh phosphate-buffered saline, and incubation 
of the cells with DMEM containing MTT for 3 hours. The 
MTT dye was reduced to purple formazan in living cells and 
the formazan generated was dissolved by dimethylsulfoxide. 
Absorbance of the solution in each well was measured at 
570 nm using a microplate reader (MQX200R, Bio-Tek 
Instruments Inc, Winooski, VT). The cells that received no 
dendrimer were set as positive controls to 100% viability. 
The viabilities of the PAMAM and PPI dendrimers were 
expressed as a percentage of the control. Six repeats were 
conducted for each sample.
Acridine orange and ethidium bromide were used for 
morphological detection of apoptotic and necrotic cells.26 
MCF-7 and A549 cells were seeded in 24-well plates and 
cultured in the absence or presence of dendrimers (14.5 µM 
PAMAM or PPI dendrimer in DMEM) for 12 hours before 
the acridine orange/ethidium bromide double staining 
  experiment. The cells were rinsed in phosphate-buffered 
saline twice and incubated in acridine orange/ethidium bro-
mide containing phosphate-buffered saline (5 µg/mL acridine 
orange and 5 µg/mL ethidium bromide) at 37°C in 5% CO2 
for 10 minutes. The stained cells were then imaged using a 
fluorescence microscope (Moticam 5000, Motic Instruments 
Inc, Richmond, Canada).
Results and discussion
Drug loading ability of PAMAM  
and PPI dendrimers
Phenylbutazone is a nonsteroidal anti-inflammatory drug 
for the long-term treatment of chronic pain particularly 
due to osteoarthritis and rheumatoid arthritis. It has an 
extremely low solubility of around 74 µM in distilled 
water, indicating low bioavailability by oral administra-
tion route and challenges in preparation of injections. Here 
phenylbutazone is used as a model drug to evaluate the 
drug-loading ability of PAMAM and PPI dendrimers. As 
shown in Figure 1, the solubility of phenylbutazone was 
enhanced by a factor of 126 in the presence of 0.36 mM 
generation 3 PAMAM dendrimer, suggesting that an aver-
age number of 26 drug molecules were bound by each 
dendrimer. The solubility of phenylbutazone in PAMAM 
dendrimer solution is linear with dendrimer concentra-
tion due to increasing surface amine groups and interior 
pockets. Surprisingly, PPI dendrimer at a concentration 
of 0.36 mM only enhances phenylbutazone solubility by   
13 times, and the solubilization behavior scarcely increases 
with dendrimer concentration. Our previous studies have 
demonstrated that surface amine groups play important 
roles in drug binding and the surface ionic interactions 
contribute much more to the solubility enhancement of 
drugs than interior encapsulations by hydrophobic and 
hydrogen bond interactions.13 Here, both generation 4 PPI 
and generation 3 PAMAM dendrimers have 32 primary 
amine groups on their surface. The pKa values for these 
surface amine groups are 9.7517 and 10.527 for PPI and 
PAMAM dendrimers, respectively, and the pH value of 
the dendrimer-drug solution is in the range of 5.3–6.0 for 
PPI and 6.3–7.0 for PAMAM depending on the ratio of 
dendrimer and drug in the solution, suggesting that all the 
amine groups are protonated and the numbers of charged 
surface functionalities for both dendrimers are equal to 
each other. Therefore, the distinct solubilization behaviors 
of PAMAM and PPI dendrimers cannot be interpreted by 
the number of surface charges.
Interior hydrophobicity, pocket volume, amido groups, 
and surface charge densities should be considered in 
addition to surface charge. With regard to interior hydro-
phobicity, generation 4 PPI has a much more hydrophobic 
interior than generation 3 PAMAM, suggesting that PPI 
should be able to encapsulate more drugs in its interior 
pockets than PAMAM,16,28 which is opposite to the results 
shown in Figure 1. For pocket volume, it is known that 
the length of branching units for constructing PPI den-
drimer is much shorter than that for PAMAM dendrimer 
(4-bond versus 7-bond), thereby the size of generation 4 
PPI is much smaller than that of generation 3 PAMAM 
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Figure 1 Solubility enhancement of phenylbutazone in the presence of generation 3 
PAMAM and generation 4 PPI dendrimers.
Abbreviations: PAMAM, polyamidoamine; PPI, polypropylenimine.
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(molecular weight 3513 Da versus 6900 Da; size 2.3 nm29 
versus 3.0 nm1). A larger dendrimer size or pocket volume 
of PAMAM is likely to encapsulate more drug molecules. 
Further, the amido groups in the scaffold of PAMAM (60 
amido groups in each generation 3 PAMAM) may facilitate 
the encapsulation of phenylbutazone molecules via hydro-
gen bond interactions (N-H in the amido group as hydrogen 
bond donor and oxygen atoms in phenylbutazone as recep-
tors).21 However, the effects of pocket volume and amido 
groups should be ruled out because more phenylbutazone 
molecules were found in the cavities of PPI dendrimer, 
which is evident by NOESY analysis and will be further 
discussed in the next sections. Finally, with regard to surface 
charge density, PPI with a smaller molecular size had a 
higher surface charge density than PAMAM (19.3 × 10−3/Å2   
versus 11.3 × 10−3/Å2). Higher charge density on the 
globular surface of PPI dendrimer means steric hindrance 
during ionic binding which may decrease the amount of 
drug bound on the dendrimer surface. However, surface 
charge density was found to have a limited influence on 
the drug-loading ability of the dendrimer in our previous 
studies and cannot be a predominant factor in the distinct 
solubilization behaviors of PAMAM and PPI dendrimers 
towards phenylbutazone.25,30
A reasonable interpretation is that PPI and phenyl-
butazone complex is not stable in aqueous solution and 
may precipitate from the solution. This is confirmed by 
the disappearance of PPI dendrimer peaks in the 1H NMR 
spectra of the supernatant of PPI-phenylbutazone mixtures 
from aqueous solubility studies (data not shown). A pos-
sible reason for the precipitation of PPI-phenylbutazone 
complexes is that the PPI dendrimer is an amphiphilic 
macromolecule with a hydrophobic interior.17   Attachment 
of phenylbutazone molecules on the PPI surface via 
ionic interaction neutralizes the surface charges of the 
dendrimer, forming hydrophobic nanostructures with low 
aqueous solubility. Another reason is that phenylbutazone 
encapsulated in the congested pockets of PPI dendrimer 
may interact with the alkyl chain of PPI by strong hydro-
phobic interactions, resulting in collapse of the dendritic 
scaffold into hydrophobic pellets and precipitation of 
the PPI-phenylbutazone complex from the solution.22 
  Perhaps a combined effect of the two factors contributes 
to precipitation of the complex. In the case of the PAMAM 
dendrimer, its interior cavities are much larger than those 
of PPI and the microenvironment of PAMAM is relatively 
hydrophilic, which make drug complexes with PAMAM 
more soluble than those with PPI in aqueous solutions. 
Precipitation of PPI-phenylbutazone complexes and 
stability of the PAMAM-phenylbutazone complex were 
further confirmed by a gradient-feed method.
Drug-loading ability of PAMAM  
and PPI dendrimers
Using the gradient-feed method, equivalent amounts of phe-
nylbutazone were added into the dendrimer solutions in a 
stepwise manner rather than single addition of excess drugs 
in the phase solubility test. As shown in Figure 2, a similar 
amount of phenylbutazone was bound by PAMAM and PPI 
dendrimers at the initial steps of the gradient-feed experiment. 
The drugs solubilized by both dendrimers increased linearly 
with the total amount of added drugs at this stage, which is 
attributed to the equivalent number of surface charges and 
interior pockets for generation 3 PAMAM and generation 
4 PPI dendrimer. A maximum amount of phenylbutazone 
(2.4 mg) solubilized by PPI dendrimer was obtained at the 
ninth step when a cumulative amount of 3.6 mg phenylbuta-
zone was fed, and a remarkable decrease in the amount of 
solubilized drug by PPI was observed in the following steps. 
The drug concentration decreased to 0.11 mg/mL which 
is slightly higher than the solubility of phenylbutazone in 
distilled water at the twentieth step, and white particles were 
found on the walls of the microtest tubes, suggesting precipita-
tion of PPI-drug complexes during this period. As discussed 
above, precipitation of PPI and phenylbutazone complexes 
is caused by neutralization of surface charges on the surface 
of PPI dendrimer with a hydrophobic interior and/or the col-
lapse of PPI scaffolds by strong hydrophobic interactions. 
The phenylbutazone amount of 2.4 mg can be recognized as 
the maximum drug-loading capacity for 0.14 mM generation 
4 PPI dendrimer in 4 mL water. In the case of the PAMAM 
dendrimer, the amount of phenylbutazone dissolved in den-
drimer solution linearly increases from 0.28 to 3.6 mg in the 
first 13 steps, followed by a slight increase in drug concen-
tration, and the drug does not reach its saturation point in 
PAMAM solution even at the twentieth step. Therefore, the 
PAMAM-phenylbutazone complex is much more stable than 
the PPI-drug complex in aqueous solution, which explains the 
difference in solubilization behavior between the PAMAM 
and the PPI dendrimer in the phase solubility studies. It is 
concluded that the results obtained from phase solubility stud-
ies cannot fully clarify the loading ability of the dendrimer, 
given that the PPI dendrimer failed to enhance the solubility 
of phenylbutazone greatly, but exhibited high drug-loading 
efficiency before a maximum loading amount was achieved 
in the gradient-feed experiment.
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Figure 2 Comparison of drug-loading ability of generation 3 PAMAM and generation 4 PPI dendrimers using a gradient-feed method.
Abbreviations: PAMAM, polyamidoamine; PPI, polypropylenimine.
Characterization of PAMAM-
phenylbutazone and PPI-phenylbutazone
To clarify the structural differences between PAMAM and 
PPI dendrimers and their influence on drug-loading, 1H NMR 
and NOESY spectra of the dendrimers and their complexes 
with phenylbutazone were obtained. As shown in Figure 3, 
generation 4 PPI dendrimer has four groups of peaks in D2O 
which are assigned as protons HA, HB′, HB′ and HC, respec-
tively, while generation 3 PAMAM dendrimers has six groups 
of peaks which are assigned as Ha, Hb, Hb′, Hc, Hd, and Hd′, 
respectively.3,18 Protons (Hc) of PPI and protons (Hb′ and Hd′) 
of PAMAM exhibit significant downfield shifts in dendrimer-
phenylbutazone complexes as compared with that in free 
dendrimers. In addition, significant upfield shifts for other 
protons of PPI and PAMAM dendrimers are observed in the 
complexes. Previous studies have demonstrated that down-
field shift of the methylene protons located on the surface 
of amine-terminated PAMAM dendrimer is attributed to 
the ionic binding of guests on dendrimer surface (decreased 
electron density around these protons) and upfield shift of 
the interior methylene protons in PAMAM pockets might 
be caused by the hydrophobic encapsulations of the guests 
(increased electron density around these protons).21 The 
shift behaviors of protons in PAMAM and PPI dendrimers 
in the presence of phenylbutazone prove the roles of ionic 
interactions and interior encapsulations in the formation of 
dendrimer-phenylbutazone complexes.
The encapsulations of phenylbutazone molecules in 
generation 3 PAMAM and generation 4 PPI dendrimers are 
investigated by a 1H-1H NOESY study, which is always used 
to analyze the spatial distance between specific protons.21 
The presence of NOE cross-peaks between two protons in 
NOESY spectrum indicates the spatial proximity of these 
protons, and the cross-peak intensity decreases with spa-
tial distance, and increases with the number of molecules 
involved in the cross-peak.3,31 As shown in Figure 4A, strong 
cross-peaks between aromatic protons (H1–3) and the interior 
methylene protons (HA and HB) are observed, confirming that 
phenylbutazone molecules are encapsulated in the pockets 
of PPI dendrimer. The absence of cross-peaks between the 
protons (HB′ and HC) of PPI and phenylbutazone suggests 
that most of the drugs are located deep inside the interior of 
PPI, and this phenomenon is in accordance with our previous 
findings on PAMAM-drug complexes as well as the NOESY 
results for PAMAM-phenylbutazone   complexes shown in Fig-
ure 4B.21 The negative NOE cross-peaks between the aromatic 
  protons (H1–3) and the alkyl protons (H5–8) of phenylbutazone 
further demonstrate the bound of drug molecules by PPI 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3367
PAMAM versus PII dendrimersInternational Journal of Nanomedicine 2011:6
dendrimer.3,25 In case of PAMAM-phenylbutazone complex, 
cross-peaks between PAMAM and phenylbutazone are found 
between Ha–d of PAMAM and H2,3 of   phenylbutazone. The 
absence of cross-peaks between H1 and Ha–d and the absence 
of cross-peaks between H1 and H5–8 indicate that the drugs 
and dendritic scaffold are more distant from each other than 
that in PPI-phenylbutazone complex. This is attributed to the 
fact that PPI has a more hydrophobic interior than PAMAM. 
The 1H NMR and NOESY analysis concluded that both ionic 
interaction and interior encapsulation play important roles 
in the formations dendrimer-phenylbutazone complexes. 
The neutralization of surface charges on PPI surface via 
ionic interactions and the collapse of PPI structure due to 
strong hydrophobic interactions may lead to the precipitation 
of PPI-phenylbutazone complexes which is confirmed in a 
previous section.
Release behavior of phenylbutazone  
from PAMAM and PPI complexes
To reveal further the structure differences in PAMAM and 
PPI dendrimer, in vitro release behaviors of phenylbutazone 
from PAMAM and PPI matrixes were investigated. As shown 
in Figure 5, generation 3 PAMAM dendrimer shows better 
sustained release ability than generation 4 PPI dendrimer, ie, 
only 13% of the drug was found in outer phase of the dialy-
sis bag after 12 hours for PAMAM, while 44% of the drug 
released from PPI-drug complex during the same period. In 
phase solubility and gradient-feed experiments, the   generation 
3 PAMAM dendrimer shows better capacity in loading phe-
nylbutazone molecules compared with the   generation 4 PPI 
dendrimer at high phenylbutazone/dendrimer feeding ratios, 
and the generation 3 PAMAM-phenylbutazone complex is 
much more stable in aqueous solution than in the generation 
4 PPI-phenylbutazone complex. Therefore, a faster release of 
phenylbutazone was obtained from PPI than from PAMAM. 
Drug carriers with ideal sustained release behavior can 
improve drug bioavailability, decrease side effects of a drug 
at a high concentration, simplify the dosing schedule, and are 
beneficial for practical applications.32 A PAMAM dendrimer 
which exhibits a much slower release rate for phenylbuta-
zone should be a better candidate in the development of 
  dendrimer-phenylbutazone formulations than PPI dendrimer. 
Perhaps chemical modification of PPI surface with hydrophilic 
moieties such as PEG chains and acetyl groups may increase 
the stability of the dendrimer-drug complex, improve solubil-
ity and delivery efficacy of the PPI dendrimer,33 and solve the 
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serious toxicity problem of the PPI dendrimer which will be 
discussed in the next section.
Comparison of cytotoxicity on PAMAM 
and PPI dendrimers
An MTT assay was conducted to compare the cytotoxicity of 
PAMAM and PPI dendrimers. Figure 6A shows the toxicity 
of PAMAM and PPI dendrimers in A549 cells. Generation 3 
PAMAM is not toxic at concentrations up to 72 µM, while 
generation 4 PPI exhibits cytotoxicity at a concentration of 
1.4 µM, suggesting that generation 4 PPI is at least 50 times 
more toxic to A549 cells than generation 3 PAMAM. Similar 
results were obtained for MCF-7 cells as shown in Figure 6B. 
The IC50   values of generation 4 PPI dendrimer in A549 and 
MCF-7 cells are 4.3 µM and 4.1 µM, respectively. An acridine 
orange/ethidium bromide double staining method was also used 
to compare the cytotoxicity of PAMAM and PPI dendrimers.26 
As shown in Figure 7, A549 and MCF-7 cells incubated with 
generation 3 PAMAM are viable (green), but cells treated with 
generation 4 PPI dendrimer at an equivalent molar concentra-
tion are found at a lower cell density and cells in necrosis 
with orange nuclei. Previous studies have found that primary 
amine groups on the dendrimer surface interact with phos-
pholipids in the cell membrane,33 followed by disturbance of 
these amphiphilic molecules and formation of holes in the cell 
membrane, resulting in leakage of intracellular components.34 
Cationic dendrimers were reported to destroy mitochondrial 
membranes, leading to the generation of reactive oxygen   species 
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causing oxidative stress, DNA damage, and apoptosis.35,36 The 
removal of surface amine groups by acetylation or PEGylation 
can effectively decrease the cytotoxicity of PAMAM and PPI 
dendrimers,23,37 indicating that surface charge plays an impor-
tant role in the cytotoxicity of both dendrimers.34 Generation 3   
PAMAM and generation 4 PPI have equivalent numbers of 
primary amine groups (pKa about 10) which are fully proto-
nated under physiological conditions (pH about 7.4). Also, they 
have a similar pH-buffering capacity due to the same amount 
of tertiary amine groups, indicating similar escape abilities 
for PAMAM and PPI from endosomes after cellular uptake.37 
Therefore, other factors including dendrimer size and interior 
hydrophobicity, are proposed to explain the distinct viability of 
cells in the presence of generation 3 PAMAM and generation 4 
PPI.   Dendrimer cytotoxicity was found to be proportional to 
  dendrimer size or generation in many cell lines,34 ie, generation 4   
and 5 PAMAM dendrimers show much higher cytotoxicity 
to MCF-7 cells than generation 3 PAMAM dendrimers at an 
equivalent concentration of surface charge (Figure 8). Also, 
high-generation PPI dendrimer displayed higher cytotoxicity 
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than low-generation PPI dendrimer on many cell lines.34,38 
In that situation, generation 4 PPI should be more biocompatible 
than generation 3 PAMAM with a larger size and equivalent 
amount of surface charge. Perhaps the unique hydrophobic 
interior of PPI plays an important role in the serious toxicity 
of the PPI dendrimer. Detailed mechanisms for this interesting 
phenomenon are still under investigation.
Conclusion
In the present study, we compared the drug loading abil-
ity, release behavior, and cytotoxicity of generation 3 
PAMAM and generation 4 PPI dendrimers. As shown in 
Table 1,   generation 3 PAMAM showed better performance 
in solubilization and release of phenylbutazone molecules 
than did generation 4 PPI with the same number of sur-
face amine groups. Also, generation 4 PPI dendrimer was 
at least 50 times more toxic than generation 3 PAMAM 
dendrimer to MCF-7 and A549 cells. The generation 4 PPI-
phenylbutazone complex is not as stable as the generation 
3 PAMAM-phenylbutazone complex and precipitates from 
aqueous solution above the maximum loading capacity. NMR 
studies confirmed strong hydrophobic interactions between 
phenylbutazone molecules and dendritic scaffolds in the 
interior pockets of the   generation 4 PPI dendrimer, which is 
proposed to be the major reason behind precipitation of the 
generation 4 PPI-  phenylbutazone complex. In conclusion, 
generation 3 PAMAM dendrimers are better candidates 
for development of a phenylbutazone formulation, while 
generation 4 PPI dendrimers should be surface-modified 
to improve their performance in terms of drug-loading and 
release and to solve their toxicity problems before being 
used as drug carriers.39
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